Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
Key Financial Performance
Revenue $7.5 million, growth of 9% from $6.9 million in the prior year first quarter.
System Revenue $2 million, compared to $2.6 million in the prior year first quarter.
Recurring Revenue $5.5 million, compared to $4.3 million in the prior year first quarter.
Gross Margin 54% of revenue, with recurring revenue gross margin at 68% and system gross margin at 15%.
Operating Expenses $10 million, including $3.2 million in non-cash charges, compared to adjusted operating expenses of $6.8 million, up from $6.1 million in the prior year.
Operating Loss $5.9 million, compared with $4.7 million in the previous year.
Net Loss $5.8 million, compared with $4.5 million in the previous year.
Free Cash Flow Negative $1.8 million, compared to negative $2.3 million in the previous year.
Cash and Cash Equivalents $10.7 million, with no debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Map-iT Catheters: Sales in the first quarter were over $1 million, with a 30% sequential growth in the U.S.
MAGiC Catheter: Received European approval and began commercial efforts across EU hospitals, expecting revenue to reach approximately $1 million per quarter by the end of the year.
GenesisX: First purchase order received in Q1, with initial soft launch planned and first commercial installation expected this summer.
Market Expansion in Europe: Initial adoption of MAGiC at approximately 20% of hospital customers, with ongoing administrative efforts for broader sales.
GenesisX Launch: Showcased at major electrophysiology conferences, receiving positive feedback from key opinion leaders.
Recurring Revenue Growth: Recurring revenue for Q1 was $5.5 million, up from $4.3 million year-over-year.
Operational Efficiencies: Expecting recurring revenue margins to return to normal levels by Q3 2025.
Strategic Focus: Core strategy includes building a portfolio of proprietary catheters and expanding the installed base of robotic accounts.
Regulatory Milestones: Six active regulatory reviews ongoing, with expectations for multiple product approvals in the near term.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Structural Challenges: The company faces significant headwinds from the structural challenges of its old product ecosystem, which may hinder growth.
Regulatory Approval Delays: The company is working through administrative submissions for the MAGiC catheter in Europe, which may delay revenue generation.
Market Awareness and Adoption: There is a gradual process required to generate awareness and interest in new products, which may slow initial adoption rates.
Supply Chain and Manufacturing: The company is preparing its supply chain and manufacturing processes for a full launch of GenesisX, which could face challenges.
Economic Uncertainty in China: Ongoing macroeconomic conditions in China create uncertainty regarding the ability of hospitals to purchase Genesis systems.
Tariffs Impact: Current tariffs are expected to cause less than a 1% increase in expenses, which could affect overall profitability.
Cash Flow Concerns: Despite reduced cash use expectations, the company reported a negative free cash flow of $1.8 million in Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Recurring Revenue Growth: Recurring revenue growth in Q1 reflects predominantly the contribution of the Map-iT family of differentiated diagnostic EP catheters, with sales over $1 million and a 30% sequential growth in the U.S.
MAGiC Catheter: Received European approval for MAGiC catheter, expecting revenue to ramp up significantly, reaching approximately $1 million per quarter by the end of 2025.
GenesisX Launch: First GenesisX purchase order received, with initial soft launch planned and full launch expected shortly after initial commercial use.
Regulatory Approvals: Six active regulatory reviews ongoing, with expectations for U.S. approval of MAGiC and GenesisX in the second half of 2025.
Revenue Guidance: Reiterating expectation of double-digit revenue growth for full year 2025, with system revenue fluctuating between $2 million to $3 million per quarter.
Recurring Revenue Expectations: Expecting recurring revenue to reach $7 million in Q4 2025.
Cash Use: Expect reduced cash use in 2025 compared to 2024, with a relatively flat cash balance.
Tariffs Impact: Anticipated to cause less than a 1% increase to expenses.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide insights on the backlog for Genesis and GenesisX mobile systems in the U.S. and Europe? Is the capital equipment environment still healthy?
A:The capital environment varies by region. In the U.S., the ecosystem is less advanced, with no MAGiC or catheter approvals yet, making it a tougher market. There is interest from hospitals, but we are waiting for approvals to make it actionable. In Europe, there is a more robust pipeline for both Genesis and GenesisX, with ongoing interest from hospitals.
Q:What feedback have you received from European customers regarding the MAGiC RF inflation catheter?
A:The reception has been very positive, with usage across a full spectrum of procedures. We expect MAGiC in Europe to scale to about a $1 million run rate by the end of the year.
Q:How have ordering patterns looked for the 20% of customers now using MAGiC?
A:Initial orders are typically for five to ten catheters, and we ensure training and support for a smooth transition. Positive feedback has led to repeat orders from some hospitals.
Q:What is the status of the FDA submission process for MAGiC in the U.S.?
A:The FDA is conducting a detailed review and has provided specific questions and comments. We are addressing these and compiling clinical data from Europe to share with the FDA.
Q:What is the timeline for full conversion to MAGiC in the U.S. and Europe?
A:Full conversion is expected to take about two years, with Europe likely seeing substantial conversion by 2026.
Q:Are you discussing alternative financing models for GenesisX with hospitals?
A:Currently, we are focusing on sales models, but we plan to present hospitals with purchase, leasing, and placement models to streamline adoption.
Q:How do you envision the case mix for robotic magnetic navigation cardiac ablation procedures evolving?
A:The current focus is on VTs, PVCs, and congenital patients, which will likely persist. As we gain acceptance, we expect to expand into SVTs and AF cases.
Q:What is the status of the EMAGIN guide catheter and its adoption in the neurovascular community?
A:The EMAGIN guide catheter has been submitted for approval, and we expect it to provide significant value in navigating complex cases. Adoption will likely be slower in the neuro field but is anticipated to grow as GenesisX becomes available.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for the approval of MAGiC in the U.S. and the exact impact of the capital environment on their sales. Additionally, there was vague language regarding the potential for an onsite audit of the manufacturing facility, leaving uncertainty about its necessity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI effort
APT Map
ATT acquisition
ATT technology
Adam Maeder
Body effort
CE Marks
CEO Peery
Cowen Conference
Diego Stereotaxis
EHRA Vienna
EMAGIN robot
EP community
EP surgery
ET afternoon
EU Notified
EU approval
EU hospital
Genesis order
Genesis system
MAGiC FDA
MAGiC Sweep
Map catheter
account
approval MAGiC
approval driver
awareness
base
booth
cath lab
catheter MAGiC
hospital effort
installation
interaction
level
purchase
question FDA
razor
summer
topic
STXS Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while there are promising developments like ramping up MAGiC catheter production and GenesisX system expansion, financial performance in Q1 2026 was weak with declining revenues and increased losses. The Q&A reveals confidence in future growth, yet lacks concrete timelines and details, which could cause investor hesitation. Given the absence of a market cap and the mixed sentiment, the stock price is likely to remain stable, resulting in a neutral prediction.
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call reveals mixed elements: a strong product pipeline with FDA approvals and optimistic future revenue growth, but current challenges include negative free cash flow, operating losses, and manufacturing issues. The Q&A highlights stable revenue from existing products and positive feedback on new launches, but also concerns about manufacturing constraints and management's vague responses on key issues. These factors balance each other out, leading to a neutral sentiment.
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
STXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
